Your session is about to expire
← Back to Search
Glutamate Receptor Antagonist
perampanel for Essential Tremor
Phase 2
Waitlist Available
Led By Charles A Handforth, M.D.
Research Sponsored by VA Greater Los Angeles Healthcare System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40 weeks
Awards & highlights
All Individual Drugs Already Approved
Summary
Obtain information on whether the medication Perampanel reduces tremor in people with essential tremor and is well-tolerated.
Eligible Conditions
- Essential Tremor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 40 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety. Laboratory testing; screen visit testing
Safety. vitals;
Safety; laboratory testing
+5 moreSecondary study objectives
QOLIE changes
Subjective assessment of global life changes
Treatment effects on Daily Living (The QUEST scale to assess quality of life)
Side effects data
From 2021 Phase 4 trial • 54 Patients • NCT0328812928%
Dizziness
17%
Fatigue
15%
Somnolence
11%
Vomiting
9%
Nasopharyngitis
9%
Headache
9%
Irritability
7%
Nausea
7%
Ear infection
6%
Upper respiratory tract infection
6%
Balance disorder
6%
Memory impairment
6%
Aggression
6%
Depression
6%
Oropharyngeal pain
2%
Sudden unexplained death in epilepsy
2%
Transient ischaemic attack
2%
Mental status changes
2%
Suicidal ideation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Perampanel 12 mg
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: perampanelExperimental Treatment1 Intervention
Perampanel administration
Group II: placeboPlacebo Group1 Intervention
Placebo administered to subjects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perampanel
FDA approved
Find a Location
Who is running the clinical trial?
VA Greater Los Angeles Healthcare SystemLead Sponsor
51 Previous Clinical Trials
8,401 Total Patients Enrolled
2 Trials studying Essential Tremor
41 Patients Enrolled for Essential Tremor
Charles A Handforth, M.D.Principal InvestigatorVHAGLAHS
Share this study with friends
Copy Link
Messenger